{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T10:24:41Z","timestamp":1777890281138,"version":"3.51.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Departamento de Ci\u00eancia e Tecnologia"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01 AI069923"],"award-info":[{"award-number":["U01 AI069923"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01 AI172064"],"award-info":[{"award-number":["U01 AI172064"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 A1120790"],"award-info":[{"award-number":["R01 A1120790"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["F31 AI152614"],"award-info":[{"award-number":["F31 AI152614"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis (TB) treatment\u2013related adverse drug reactions (TB-ADRs) can negatively affect adherence and treatment success rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We developed prediction models for TB-ADRs, considering participants with drug-susceptible pulmonary TB who initiated standard TB therapy. TB-ADRs were determined by the physician attending the participant, assessing causality to TB drugs, the affected organ system, and grade. Potential baseline predictors of TB-ADR included concomitant medication (CM) use, human immunodeficiency virus (HIV) status, glycated hemoglobin (HbA1c), age, body mass index (BMI), sex, substance use, and TB drug metabolism variables (NAT2 acetylator profiles). The models were developed through bootstrapped backward selection. Cox regression was used to evaluate TB-ADR risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 156 TB-ADRs among 102 of the 945 (11%) participants included. Most TB-ADRs were hepatic (n = 82 [53%]), of moderate severity (grade 2; n = 121 [78%]), and occurred in NAT2 slow acetylators (n = 62 [61%]). The main prediction model included CM use, HbA1c, alcohol use, HIV seropositivity, BMI, and age, with robust performance (c-statistic = 0.79 [95% confidence interval {CI}, .74\u2013.83) and fit (optimism-corrected slope and intercept of \u22120.09 and 0.94, respectively). An alternative model replacing BMI with NAT2 had similar performance. HIV seropositivity (hazard ratio [HR], 2.68 [95% CI, 1.75\u20134.09]) and CM use (HR, 5.26 [95% CI, 2.63\u201310.52]) increased TB-ADR risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The models, with clinical variables and with NAT2, were highly predictive of TB-ADRs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiae025","type":"journal-article","created":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T20:14:01Z","timestamp":1706040841000},"page":"813-823","source":"Crossref","is-referenced-by-count":5,"title":["Prediction Models for Adverse Drug Reactions During Tuberculosis Treatment in Brazil"],"prefix":"10.1093","volume":"229","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3377-1026","authenticated-orcid":false,"given":"Felipe","family":"Ridolfi","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , USA"},{"name":"Instituto Nacional de Infectologia Evandro Chagas, Funda\u00e7\u00e3o Oswaldo Cruz , Rio de Janeiro, Rio de Janeiro , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo","family":"Amorim","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren S","family":"Peetluk","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , USA"},{"name":"Optum Epidemiology , Boston, Massachusetts , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W","family":"Haas","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cody","family":"Staats","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Ara\u00fajo-Pereira","sequence":"additional","affiliation":[{"name":"Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative , Salvador, Bahia , Brazil"},{"name":"Faculdade de Tecnologia e Ci\u00eancias, Curso de Medicina , Salvador, Bahia , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcelo","family":"Cordeiro-Santos","sequence":"additional","affiliation":[{"name":"Funda\u00e7\u00e3o Medicina Tropical Dr Heitor Vieira Dourado , Manaus, Amazonas , Brazil"},{"name":"Universidade do Estado do Amazonas , Manaus, Amazonas , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afr\u00e2nio L","family":"Kritski","sequence":"additional","affiliation":[{"name":"Faculdade de Medicina, Universidade Federal do Rio de Janeiro , Rio de Janeiro, Rio de Janeiro , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina C","family":"Figueiredo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno B","family":"Andrade","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , USA"},{"name":"Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative , Salvador, Bahia , Brazil"},{"name":"Faculdade de Tecnologia e Ci\u00eancias, Curso de Medicina , Salvador, Bahia , Brazil"},{"name":"Laborat\u00f3rio de Pesquisa Cl\u00ednica e Translacional, Instituto Gon\u00e7alo Moniz, Funda\u00e7\u00e3o Oswaldo Cruz , Salvador, Bahia , Brazil"},{"name":"Curso de Medicina, Universidade Salvador , Salvador, Bahia , Brazil"},{"name":"Curso de Medicina, Escola Bahiana de Medicina e Sa\u00fade P\u00fablica , Salvador, Bahia , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria C","family":"Rolla","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Infectologia Evandro Chagas, Funda\u00e7\u00e3o Oswaldo Cruz , Rio de Janeiro, Rio de Janeiro , Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R","family":"Sterling","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center , Nashville, Tennessee , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Regional Prospective Observational Research in Tuberculosis (RePORT)\u2013Brazil Consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavia M","family":"Sant\u2019Anna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamile Garcia","family":"de Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o","family":"Marin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Rezende","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna Cristina","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bet\u00e2nia","family":"Nogueira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Brito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Spener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,1,23]]},"reference":[{"key":"2024031408562099600_jiae025-B1","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2024031408562099600_jiae025-B2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/0003-4819-76-3-112-6-407","article-title":"A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen","volume":"112","author":"Cohn","year":"1990","journal-title":"Ann Intern Med"},{"key":"2024031408562099600_jiae025-B3","volume-title":"Global tuberculosis report 2022","author":"World Health Organization (WHO)","year":"2022"},{"key":"2024031408562099600_jiae025-B4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00228-016-2083-4","article-title":"Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring","volume":"72","author":"Verbeeck","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"2024031408562099600_jiae025-B5","doi-asserted-by":"crossref","first-page":"748310","DOI":"10.3389\/fitd.2021.748310","article-title":"Adverse drug reactions related to treatment of drug-susceptible tuberculosis in Brazil: a prospective cohort study","volume":"2","author":"Sant\u2019Anna","year":"2022","journal-title":"Front Trop Dis"},{"key":"2024031408562099600_jiae025-B6","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/thx.2006.058867","article-title":"Adverse events and treatment interruption in tuberculosis patients with and without HIV co-infection","volume":"61","author":"Breen","year":"2006","journal-title":"Thorax"},{"key":"2024031408562099600_jiae025-B7","doi-asserted-by":"crossref","first-page":"625078","DOI":"10.3389\/fphar.2021.625078","article-title":"Adherence and associated factors of treatment regimen in drug-susceptible tuberculosis patients","volume":"12","author":"Bea","year":"2021","journal-title":"Front Pharmacol"},{"key":"2024031408562099600_jiae025-B8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/cid\/ciab598","article-title":"A clinical prediction model for unsuccessful pulmonary tuberculosis treatment outcomes","volume":"74","author":"Peetluk","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2024031408562099600_jiae025-B9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijid.2020.11.140","article-title":"Novel stepwise approach to assess representativeness of a large multicenter observational cohort of tuberculosis patients: the example of RePORT Brazil","volume":"103","author":"Arriaga","year":"2021","journal-title":"Int J Infect Dis"},{"key":"2024031408562099600_jiae025-B10"},{"key":"2024031408562099600_jiae025-B11","volume-title":"Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update","author":"World Health Organization (WHO)","year":"2017"},{"key":"2024031408562099600_jiae025-B12","volume-title":"Manual de recomenda\u00e7\u00f5es para o controle da tuberculose no Brasil","author":"Minist\u00e9rio da Sa\u00fade","year":"2018"},{"key":"2024031408562099600_jiae025-B13","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2024031408562099600_jiae025-B14","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"2024031408562099600_jiae025-B15","volume-title":"Table for grading the severity of adult and pediatric adverse events corrected version 2.0","author":"National Institute of Allergy and Infectious Diseases, Division of AIDS","year":"2014"},{"key":"2024031408562099600_jiae025-B16","doi-asserted-by":"crossref","first-page":"2100804","DOI":"10.1183\/13993003.00804-2021","article-title":"World Health Organization treatment outcome definitions for tuberculosis: 2021 update","volume":"58","author":"Linh","year":"2021","journal-title":"Eur Respir J"},{"key":"2024031408562099600_jiae025-B17","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.diabres.2011.06.025","article-title":"Glycated haemoglobin (HbA1c) for the diagnosis of diabetes mellitus\u2014practical implications","volume":"93","author":"Colagiuri","year":"2011","journal-title":"Diabetes Res Clin Pract"},{"issue":"Suppl 1","key":"2024031408562099600_jiae025-B18","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.2337\/dc20-S002","article-title":"Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142020","volume":"43","author":"American Diabetes Association","year":"2020","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"2024031408562099600_jiae025-B19","first-page":"51S","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults\u2014the evidence report.","volume":"6","author":"National Institutes of Health","year":"1998","journal-title":"Obes Res"},{"key":"2024031408562099600_jiae025-B20","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s00228-022-03362-7","article-title":"Influence of N-acetyltransferase 2 (NAT2) genotype\/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models","volume":"78","author":"Thomas","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"2024031408562099600_jiae025-B21","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1164\/rccm.202103-0564OC","article-title":"A rapid pharmacogenomic assay to detect NAT2 polymorphisms and guide isoniazid dosing for tuberculosis treatment","volume":"204","author":"Verma","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2024031408562099600_jiae025-B22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.5588\/ijtld.11.0377","article-title":"NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis","volume":"16","author":"Wang","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024031408562099600_jiae025-B23","doi-asserted-by":"crossref","first-page":"e0269765","DOI":"10.1371\/journal.pone.0269765","article-title":"Impact of adverse drug reactions on the outcomes of tuberculosis treatment","volume":"18","author":"Sant\u2019Anna","year":"2023","journal-title":"PLoS One"},{"key":"2024031408562099600_jiae025-B24","doi-asserted-by":"crossref","first-page":"e0227101","DOI":"10.1371\/journal.pone.0227101","article-title":"Impact of the change in the antitubercular regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: a retrospective cohort study","volume":"14","author":"Arriaga","year":"2019","journal-title":"PLoS One"},{"key":"2024031408562099600_jiae025-B25","first-page":"144","article-title":"Incidence and risk factors of major toxicity associated to first-line antituberculosis drugs for latent and active tuberculosis during a period of 10 years","volume":"21","author":"Castro","year":"2015","journal-title":"Rev Port Pneumol (2006)"},{"key":"2024031408562099600_jiae025-B26","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/bimj.201700067","article-title":"Variable selection\u2014a review and recommendations for the practicing statistician","volume":"60","author":"Heinze","year":"2018","journal-title":"Biom J"},{"key":"2024031408562099600_jiae025-B27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"2024031408562099600_jiae025-B28","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jclinepi.2015.12.005","article-title":"A calibration hierarchy for risk models was defined: from utopia to empirical data","volume":"74","author":"Van Calster","year":"2016","journal-title":"J Clin Epidemiol"},{"key":"2024031408562099600_jiae025-B29","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jclinepi.2009.03.017","article-title":"Development and validation of a prediction model with missing predictor data: a practical approach","volume":"63","author":"Vergouwe","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"2024031408562099600_jiae025-B30","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1097\/EDE.0000000000001073","article-title":"Censoring for loss to follow-up in time-to-event analyses of composite outcomes or in the presence of competing risks","volume":"30","author":"Lesko","year":"2019","journal-title":"Epidemiology"},{"key":"2024031408562099600_jiae025-B31","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/jcph.1512","article-title":"Metamizole (dipyrone) and the liver: a review of the literature","volume":"59","author":"Lutz","year":"2019","journal-title":"J Clin Pharmacol"},{"key":"2024031408562099600_jiae025-B32","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/jcpt.12422","article-title":"Safety of metamizole: a systematic review of the literature","volume":"41","author":"Andrade","year":"2016","journal-title":"J Clin Pharm Ther"},{"key":"2024031408562099600_jiae025-B33","doi-asserted-by":"crossref","first-page":"e94271","DOI":"10.1371\/journal.pone.0094271","article-title":"Evaluation of patterns of liver toxicity in patients on antiretroviral and anti-tuberculosis drugs: a prospective four arm observational study in Ethiopian patients","volume":"9","author":"Yimer","year":"2014","journal-title":"PLoS One"},{"key":"2024031408562099600_jiae025-B34","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1093\/cid\/ciz732","article-title":"High rates of drug-induced liver injury in people living with HIV coinfected with tuberculosis (TB) irrespective of antiretroviral therapy timing during antituberculosis treatment: results from the starting antiretroviral therapy at three points in TB trial","volume":"70","author":"Naidoo","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024031408562099600_jiae025-B35","first-page":"FC01-04","article-title":"Adverse drug reaction profile in patients on anti-tubercular treatment alone and in combination with highly active antiretroviral therapy","volume":"9","author":"Sadiq","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"2024031408562099600_jiae025-B36","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1086\/507543","article-title":"Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes","volume":"43","author":"Nijland","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2024031408562099600_jiae025-B37","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","article-title":"NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy","volume":"69","author":"Azuma","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"2024031408562099600_jiae025-B38","doi-asserted-by":"crossref","first-page":"990","DOI":"10.5588\/ijtld.21.0345","article-title":"Adverse effects and duration of treatment of TB in Canterbury, New Zealand","volume":"25","author":"Phillipson","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"2024031408562099600_jiae025-B39","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ijtb.2019.11.005","article-title":"Adverse drug reactions in tuberculosis and management","volume":"66","author":"Prasad","year":"2019","journal-title":"Indian J Tuberc"},{"key":"2024031408562099600_jiae025-B40","doi-asserted-by":"crossref","first-page":"e044687","DOI":"10.1136\/bmjopen-2020-044687","article-title":"Systematic review of prediction models for pulmonary tuberculosis treatment outcomes in adults","volume":"11","author":"Peetluk","year":"2021","journal-title":"BMJ Open"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiae025\/56589911\/jiae025.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/3\/813\/56967248\/jiae025.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/3\/813\/56967248\/jiae025.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T04:58:12Z","timestamp":1710392292000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/3\/813\/7585562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,23]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,1,23]]},"published-print":{"date-parts":[[2024,3,14]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiae025","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.08.28.23294721","asserted-by":"object"}]},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3,15]]},"published":{"date-parts":[[2024,1,23]]}}}